ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Hepatocellular carcinoma"

  • 2022 American Transplant Congress

    Surging Liver Transplant Rates for Alcohol-Associated Liver Disease May Exacerbate Waitlist Death of Patients with Hepatocellular Carcinoma in MMAT-3 Era

    L. Yuan1, J. L. Dodge1, K. Zhou1, N. Terrault2

    1Division of Gastrointestinal and Liver Diseases, University of Southern California, Los Angeles, CA, 2University of Southern California, Los Angeles, CA

    *Purpose: Rates of liver transplantation (LT) for alcohol-associated liver disease (ALD) have increased significantly, in part related to broader acceptance of severe alcohol hepatitis (AH)…
  • 2022 American Transplant Congress

    Disparities in Liver Transplant Access for HCC Patients Based on Patient Blood Type and the Intensity of Competition for Organs Under MMAT-3

    A. J. Ahearn, H. Chowdhry, J. L. Dodge, K. Zhou

    University of Southern California, Los Angeles, CA

    *Purpose: Recent policy changes (acuity circles and MMAT-3 for HCC MELD exception) aimed to reduce geographic disparities in access to liver transplant (LT) and mitigate…
  • 2022 American Transplant Congress

    Exploring Individual Optimal Immunosuppression Management According to the Oncological Risk in Liver Transplanted Patients with Hepatocellular Carcinoma

    K. Sasakik1, S. Kimura2, D. Soma3, K. Tomiyama4, M. Matthew4, M. Fruscione2, C. Kubal3, D. Kwon5

    1Stanford University, Palo Alto, CA, 2Massachusetts General Hospital, Belmont, MA, 3Indiana University, Indianapolis, IN, 4University of Rochester, Rochester, NY, 5Cleveland Clinic, Cleveland, OH

    *Purpose: Post-Liver transplant (LT) immunosuppression management is the only modifiable factor to prevent hepatocellular carcinoma (HCC) recurrence; however, the impact of immunosuppression on the HCC…
  • 2022 American Transplant Congress

    The Effect of Adoption of Acuity Circles on Hepatocellular Carcinoma Transplantation Rates at a Single High Acuity Center

    D. W. Victor III, J. Corkrean, S. Kodali

    Sherrie and Allan Conover Center for Liver disease and Transplantation, Houston Methodist Hospital, Houston, TX

    *Purpose: Transplantation for selected patient with HCC has been prioritized with a MELD exception since 2002. Further changes have decreased the maximum exception for HCC.…
  • 2022 American Transplant Congress

    Center-Level Variability in DDLT Rate Before and After the Implementation of MMaT/250 Score

    T. Ishaque, J. Beckett, B. King, J. G. Wang, D. Segev, A. Massie

    Johns Hopkins Medical Institutions, Baltimore, MD

    *Purpose: In 02/2020, OPTN replaced DSA/regional boundaries with acuity circles and substituted exception scores for individual patients to median-MELD-at-transplant within 250 nautical miles of a…
  • 2022 American Transplant Congress

    Cell-free Amniotic Fluid Reduces Liver Inflammation And Fibrosis

    F. Ditmars1, C. Bowen1, N. Liu1, K. L. Pereira de Castro1, J. Johnson1, M. Kueht1, A. Saad2, H. L. Stevenson3, J. Fair1, W. S. Fagg1

    1Surgery, University of Texas Medical Branch, Galveston, TX, 2Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX, 3Pathology, University of Texas Medical Branch, Galveston, TX

    *Purpose: Effective interventions for hepatic inflammation and fibrosis remain a dire unmet need in transplant medicine. Cell-free amniotic fluid (AF) represents a potential alternative to…
  • 2022 American Transplant Congress

    Locoregional Therapy and Long-Term Post-Transplant Outcomes for HCC Liver Transplant Recipients

    T. Ishaque, S. R. Weeks, A. Kolarich, J. Ruck, J. Garonzik-Wang, D. Segev, A. Massie, B. King

    Johns Hopkins Medical Institutions, Baltimore, MD

    *Purpose: In last decade, locoregional therapy (LRT) have been widely used to downstage HCC patients in order to qualify for liver transplantation. Large-scale direct comparisons…
  • 2022 American Transplant Congress

    Degree of Pre-Liver Transplant Immune Dysfunction Correlates with Post-Transplant Cancer Recurrence

    G. S. Prakash1, G. G. Panayotova1, S. Simonishvili1, Y. Qin1, L. Jin1, T. Ayorinde1, L. J. Minze2, F. Paterno1, L. Brown1, A. Amin1, D. Liu1, R. Ghobrial2, J. V. Guarrera1, K. E. Lunsford1

    1Rutgers New Jersey Medical School, Newark, NJ, 2Houston Methodist Hospital, Houston, TX

    *Purpose: Despite stringent selection criteria for liver transplant (LT) in patients with liver-limited malignancy, post-transplant cancer recurrence remains problematic. We have previously identified a pre-LT…
  • 2022 American Transplant Congress

    The Impact of Yttium-90 Radioembolization on T Cell Phenotypes in Bridged to Transplant Hepatocellular Carcinoma Patients

    K. Nunez, T. Sandow, P. Thevenot, A. Cohen

    Ochsner Health System, New Orleans, LA

    *Purpose: Response to locoregional therapy (LRT) in hepatocellular carcinoma (HCC) impacts both progression-free survival (PFS) and bridge to transplant success. Yttrium-90 (Y90) is an effective…
  • 2022 American Transplant Congress

    Clinical Efficacy of Adjuvant Immunotherapy for Liver Transplant Recipients with Exceeding Japan Criteria of Hepatocellular Carcinoma Using Donor Liver Derived Natural Killer Cells

    M. Ohira1, Y. Imaoka2, K. Sato3, K. Imaoka1, N. Tanimine1, H. Tahara1, K. Ide1, T. Kobayashi1, Y. Tanaka1, A. G. Tzakis4, S. Nishida5, H. Ohdan1

    1Hiroshima University, Hiroshima, Japan, 2Hiroshima Uni., Hiroshima, Japan, 3Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan, 4Digestive Diseases and Surgery Institute, Cleveland Clinic, Cleveland, OH, 5Univ of Miami School of Medicine, Valhalla, NY

    *Purpose: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and is an indication for liver transplantation (LT). Immunosuppressive regimens currently used after…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 23
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences